US firm expands incontinence gel trials:
This article was originally published in Clinica
Executive Summary
Protein Polymer Technologies has added an additional clinical centre to accelerate human testing of its urethral bulking agent for the treatment of female stress urinary incontinence. The product, which is being tested under an investigational device exemption, is injected into the tissues surrounding the sphincter at the base of the bladder where it forms a firm hydrogel to narrow the urethra lumen and prevent urine leakage. The San Diego, California firm expects to launch the product in the US in 2005. The company adds that estimates shows that over $3 billion is spent in the US every year on incontinence-related care.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.